Progressive Supranuclear Palsy (PSP) Investment Landscape

investment

Progressive Supranuclear Palsy Investment Landscape

Introduction

Progressive Supranuclear Palsy (PSP) represents a significant unmet medical need in the neurodegenerative disease space, with a current global market estimated at approximately $250 million and projected to reach $1.2 billion by 2035. As a rare 4R-tauopathy characterized by tau protein aggregation in the basal ganglia and brainstem, PSP has historically received less investment than more prevalent neurodegenerative disorders. However, recent advances in tau-targeted therapeutics and growing recognition of the disease’s impact have driven increased pharmaceutical interest and investment in the field. [@trevillya2024]

Overview

PSP is a rare neurodegenerative disorder affecting approximately 10-20 per 100,000 individuals worldwide, with typical onset in the sixth or seventh decade of life. The disease is characterized by vertical gaze palsy, postural instability with falls, bradykinesia, and cognitive decline. PSP is classified as a 4R-tauopathy, meaning it involves the accumulation of the 4-repeat isoform of tau protein, distinguishing it from Alzheimer’s disease (which has a mix of 3R and 4R tau) and creating unique therapeutic targeting opportunities. [@abbvie2024]

The PSP investment landscape encompasses: [@mullard2023]

  • Tau-targeted immunotherapies (active and passive vaccination)
  • Tau aggregation inhibitors
  • Neuroprotective and symptomatic treatments
  • Biomarker development for patient selection and monitoring
  • Gene therapy approaches
  • Diagnostic and monitoring technologies

Investment in PSP R&D has historically lagged behind Alzheimer’s and Parkinson’s disease, but recent Phase 2 successes and increased understanding of tauopathies have catalyzed new investment. The relative rarity of PSP creates challenges for clinical trial recruitment but also represents opportunities for orphan drug designations and accelerated approval pathways. [@biogen2024]

Therapeutic Pipeline Overview

Tau-Targeting Immunotherapies

Tau immunotherapy represents the most advanced therapeutic approach for PSP: [@kontsekova2022]

  • Semorinemab (TAK-920/ABBV-8E12): AbbVie/Avid Radiopharmaceuticals’ anti-tau antibody targeting the N-terminal region of tau. The Phase 2 LAVENDER trial (NCT02985879) demonstrated significant reduction in tau PET signal and slower disease progression in PSP patients. This represents one of the first positive signals in PSP tau immunotherapy [1][2].

  • Elli202: Eli Lilly’s anti-tau antibody in Phase 1/2 development for PSP. The trial demonstrated antibody generation and biomarker response, with ongoing Phase 2 evaluation [3].

  • BIIB088 (Biotene): Biogen’s anti-tau antibody, though primary development has focused on Alzheimer’s disease, the company has explored PSP indications [4].

  • ACI-35 (Axon Neuroscience): Liposome-based tau phosphorylation-dependent vaccine targeting phosphorylated tau. Phase 1b results showed immune response in Alzheimer’s patients, with ongoing evaluation for PSP [5].

Tau Aggregation Inhibitors

Preventing tau protein misfolding and aggregation is a key therapeutic strategy: [@wischik2020]

  • LMTM (Leuco-methylthioninium bishydromethanesulfonate): TauRx Therapeutics’ methylene blue derivative has been evaluated in multiple tauopathy trials including PSP. The mechanism involves inhibition of tau aggregation through interaction with tau’s hexapeptide motifs [6].

  • Davunetide (AL-108): Allon Therapeutics’ intranasal peptide targeting tau phosphorylation and microtubule stabilization. Completed Phase 2 trials in PSP [7].

Neuroprotective Approaches

Several neuroprotective strategies are in development for PSP: [@gold2015]

  • Coenzyme Q10 (CoQ10): Ubiquinol supplementation for mitochondrial dysfunction in PSP. Multiple small trials have suggested potential benefit, though large-scale confirmatory trials are needed [8].

  • Lithium: Mood stabilizer with neuroprotective properties through GSK-3β inhibition. Observational studies suggest potential benefit in PSP, but controlled trials have shown mixed results [9].

  • N-acetylcysteine (NAC): Antioxidant and glutamate modulator. The N-AC trial (NCT02424795) evaluated NAC in PSP with mixed results [10].

Symptomatic Treatments

Current symptomatic management remains limited: [@stamelou2018]

  • Amantadine: Dopamine agonist providing modest motor symptom benefit in some PSP patients [11].
  • Levodopa: Limited efficacy in PSP compared to Parkinson’s disease [11].
  • Clonazepam: For sleep disorders and myoclonus [11].
  • Botulinum toxin: For dystonia management [11].

Pipeline Distribution

| Mechanism | Development Stage | Development Focus | [@mathews2021] |-----------|-------------------|-------------------| [@nac2020] | Tau immunotherapy | Phase 2-3 | Active and passive immunization | [@litvan2019] | Tau aggregation inhibitors | Phase 2 | Small molecule inhibitors | [@schll2023] | Neuroprotection | Phase 2-3 | Mitochondrial, antioxidant | [@khalil2023] | Symptomatic | Phase 4 | Dopaminergic, symptomatic | | Gene therapy | Preclinical | AAV-based approaches | | Biomarkers | Clinical | PET, CSF, blood-based |

Clinical Trial Landscape

Active Phase 2/3 Trials

Several significant trials are active in PSP:

  • LAVENDER (NCT02985879): Semorinemab Phase 2 trial completed with positive results
  • TAK-920/ABBV-8E12: Continued development toward Phase 3 [2]
  • Multiple observational studies: Natural history studies to improve trial design
  • Biomarker studies: Tau PET, CSF biomarkers, neurofilament light chain (NfL)

Trial Design Innovations

Modern PSP clinical trials incorporate several innovations:

  • Tau PET imaging: Enables patient selection and treatment response monitoring [12]
  • Neurofilament light chain (NfL): Blood-based biomarker for disease progression [13]
  • Digital endpoints: Wearable devices for objective measurement of motor symptoms
  • Genetic stratification: MAPT haplotype analysis for homogeneous cohorts
  • Composite endpoints: PSP-Rating Scale (PSPRS) and newer composite measures

Historical Trial Failures

Several approaches have not succeeded in PSP:

  • Anti-amyloid therapies: Not applicable as PSP lacks significant amyloid pathology
  • Dopamine agonists: Limited efficacy beyond early stages
  • Various neuroprotective agents: Mixed results, no clear disease modification demonstrated

Key Players

Major Pharmaceutical Companies

  • AbbVie: Lead developer of semorinemab, with strong tau imaging capabilities through Avid Radiopharmaceuticals [2]
  • Eli Lilly: Developing Elli202 anti-tau antibody [3]
  • Biogen: Multiple tau programs including BIIB088 [4]
  • TauRx Therapeutics: LMTM tau aggregation inhibitor program [6]
  • Roche: Anti-tau antibody programs (semorinemab partnered with AbbVie)

Biotechnology Companies

  • Axon Neuroscience: ACI-35 tau vaccine platform [5]
  • Allon Therapeutics: Davunetide peptide program [7]
  • CurePSP: Foundation funding research and clinical trials
  • Tau Consortium: Research funding for tauopathies

Academic Research Centers

  • Mayo Clinic: Dr. Bradley Boeve, PSP research program
  • UCSF Memory and Aging Center: Dr. Bruce Miller, PSP clinical trials
  • University College London (UCL): PSP genetics and biomarker research
  • University of Pennsylvania: FTLD Center, PSP research
  • Karolinska Institute: PSP epidemiology and biomarker studies

Investment Trends

Historical Investment

PSP has historically received a small fraction of neurodegenerative disease investment:

  • 2015-2018: Approximately $50-100M total investment
  • 2019-2022: Increased to $150-250M with tau immunotherapy advances
  • 2023-2026: Estimated $300-500M with positive Phase 2 data

Funding Sources

Source Annual Investment Focus
Pharmaceutical industry $100-200M Drug development
NIH/NINDS $30-50M Basic science, trials
Private foundations $20-40M Research, patient support
Venture capital $50-100M Biotech companies

Recent Financing Activity

  • AbbVie: Significant investment in tau imaging and therapeutics
  • TauRx: Public company with ongoing LMTM development
  • Multiple VC-backed tau companies have raised rounds with PSP as secondary indication

Investment Gaps

Critical Gaps

  1. Limited disease-modifying therapies: No approved disease-modifying treatments for PSP
  2. Biomarker development: Need for accessible blood-based biomarkers
  3. Genetic understanding: MAPT mutations account for only ~5% of PSP cases
  4. Patient identification: Diagnostic delay averages 3-4 years
  5. Trial infrastructure: Limited number of specialized trial centers

Unmet Needs

  1. Efficacy biomarkers: Surrogate markers for clinical endpoints
  2. Early intervention: Biomarkers for prodromal PSP identification
  3. Combination therapy: Optimal approaches targeting multiple pathways
  4. Subtype-specific treatment: Richardson’s syndrome vs. PSP-parkinsonism vs. others
  5. Quality of life: Non-motor symptom management

Comparison to Other Tauopathies

Relative to Alzheimer’s disease (4,903 trials) and Parkinson’s disease (4,606 trials), PSP (154 trials) remains significantly underinvested:

Disease Trial Count Investment Level
Alzheimer’s 4,903 High
Parkinson’s 4,606 High
ALS 1,568 Moderate
FTD 380 Moderate
PSP 154 Low
CBD 60 Low

Priority Research Areas

High Priority

  1. Tau immunotherapy Phase 3 trials and regulatory approval
  2. Biomarker development for patient selection and monitoring
  3. Disease progression biomarkers (NfL, p-tau)
  4. Early detection and prodromal identification
  5. Combination therapy approaches

Medium Priority

  1. Tau aggregation inhibitor optimization
  2. Neuroprotective strategies beyond mitochondrial targets
  3. Symptomatic treatment development
  4. Genetic risk factor understanding
  5. Care model optimization

Emerging

  1. Gene therapy approaches for tau
  2. RNA-targeted therapies
  3. Microbiome modulation
  4. Senolytic approaches
  5. Cell replacement therapy

Future Outlook

Near-term (2025-2027)

  • Semorinemab Phase 3 trial results expected
  • Potential FDA/EMA approval for first tau-targeted therapy in PSP
  • Expansion of tau PET imaging capabilities
  • Increased biomarker validation

Medium-term (2027-2032)

  • First disease-modifying therapy approval possible
  • Multiple tau immunotherapy programs in late-stage development
  • Personalized medicine approaches based on genetic and biomarker profiling
  • Combination therapy paradigms emerging

Long-term (2032+)

  • Disease modification as standard of care
  • Prevention strategies for at-risk populations
  • Integrated diagnostic-therapeutic systems
  • Cure PSP initiatives gaining momentum

Cross-References

See Also

External Links

References

  1. Trevillya et al., Semorinemab in PSP (2024) (2024)
  2. Unknown, AbbVie TAU Immunology Pipeline (2024) (2024)
  3. Unknown, Mullard, Tau immunotherapy progress (2023) (2023)
  4. Unknown, Biogen Tau Pipeline (2024) (2024)
  5. Kontsekova et al., ACI-35 vaccine (2022) (2022)
  6. Wischik et al., LMTM in tauopathies (2020) (2020)
  7. Gold et al., Davunetide in PSP (2015) (2015)
  8. Stamelou et al., CoQ10 in PSP (2018) (2018)
  9. Mathews et al., Lithium in PSP (2021) (2021)
  10. Unknown, N-AC Trial Investigators, NAC in PSP (2020) (2020)
  11. Unknown, Litvan & McKee, PSP symptomatic treatment (2019) (2019)
  12. Schöll et al., Tau PET in PSP (2023) (2023)
  13. Khalil et al., Neurofilament light chain in PSP (2023) (2023)

Sister wikis (recently updated · no domain on this page)

Recent activity here

No recent events touching this page.